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Use of Imaging in Restorative Stroke Trials
Steven C. Cramer, MD
Abstract—Restorative therapies aim to improve behavioral outcome after stroke by promoting repair and restoration.
Measures of CNS injury and function might be useful to evaluate such therapies in a clinical trial, for example, by
optimizing patient selection or treatment dose. These issues are considered in this review, with specific examples
provided. (Stroke. 2009;40[suppl 1]:S28-S29.)
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A restorative stroke trial is one that evaluates a restorativetherapy in patients with stroke. A restorative therapy can
be defined as one that aims to improve outcome by promoting
repair and restoration rather than by salvaging acutely threat-
ened tissue. If stroke is considered to be expressed in three
phases (Figure), a restorative trial would take place in the
subacute or chronic phase.
Restorative interventions under study have included
growth factors, cells, small molecules, intensive and activity-
based therapy, robotics, neuroprosthetics, electromagnetic
brain stimulation, and cognitive strategies such as motor
imagery. Therapies initiated in the first few days after stroke
typically remain in the preclinical1,2 or early clinical (eg,
ClinicalTrials.gov Identifier: NCT00362414) stage. Some
therapies initiated in the chronic phase have demonstrated
positive effects in human subjects.3,4
Note that the effectiveness of such interventions is influ-
enced by activity, experience, environment, and psychosocial
factors.
Imaging Measures of Potential Interest to
Restorative Stroke Trials
A restorative stroke trial might incorporate any of several
neuroimaging measures. In general, the purpose of using such
measures is to provide insights not available at the bedside,
such as those related to injury or CNS function.
A wide range of imaging measures is of potential interest
toward these goals. Measures of injury include traditional
anatomic methods, such as infarct volume on CT or MRI.
High resolution MRI can detect changes in cortical thickness,
sometimes increased with treatment. Physiological measures
such as motor system transcranial magnetic stimulation
(TMS) can yield information on the size of a cortical
representational map, or on the speed/magnitude of the motor
evoked potential (MEP), reflections of CNS injury. Diffusion
tensor imaging (DTI) measures the tendency of water move-
ment to be directional, and so reflects injury when stroke
reduces the linearity of water movement within a directional
tract such as the corticospinal.
Measures of tissue function might also be useful for
assisting decision making in the setting of a restorative trial.
Brain function can be measured with functional MRI (fMRI)
or positron emission tomography (PET), as well as with
electroencephalography or magnetoencephalography. Use of
such methods, particularly fMRI or PET, can measure the
volume of regional activation, such as the volume of Broca’s
area activated during a speech output task; the magnitude of
activation, such as the height of parietal activation during a
spatial attention task; or the balance of activation across
hemispheres, sometimes reported as the laterality index. PET
can provide a direct measure of regional blood flow or
metabolism. Other tissue function measures include measures
of excitability or inhibition, or assessments of the connectiv-
ity between various cortical regions.
Measurement of tissue function introduces complexities
that do not arise with measurement of tissue structure. To
activate the brain with fMRI or PET, the subject must engage
in a specific behavioral paradigm, correctly, according to
instructions, on cue, at times a challenge after stroke. The
behavioral paradigm must be carefully selected to probe the
brain functional circuit of interest.
Use of Imaging Measures in Restorative
Stroke Trials
Many potential routes exist whereby the information intro-
duced by imaging measurements might be used to improve a
restorative stroke trial.
Imaging measures might be used to identify distinct patient
subgroups. Selectively enriching the study enrollee pool in
effect means that imaging measures might thus serve as entry
criteria. For example, one might enroll only those patients
with a certain amount of motor system dysfunction on the
basis of the MEP measured with TMS, or on the basis of
injury extent to a specific CNS functional system.
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Imaging measures might be used to predict treatment gains.
Predictive measures might be valuable as an additional
approach to refine entry criteria. Recent studies provide
examples whereby a specific measure of CNS function was
able to predict response to a restorative treatment; for
example, a DTI-based measure of CNS injury at baseline
accounted for 38% of the variance in clinical gains5; an
fMRI-based measure of CNS function, 20%.6 Use of such
measures as entry criteria might therefore improve the ability
of a clinical trial to detect a treatment-related effect. Further
studies are needed to verify, and to clarify, such observations.
Imaging measures might be used to guide treatment deci-
sions for subjects in a trial. For example, serial imaging
measures can be used to individualize details of therapy,
much as acute stroke trials such as the Interventional Man-
agement of Stroke II trial sometimes vary features of treat-
ment; in that trial, choice of catheter and dose of thrombolytic
were adjusted based on serial angiograms.7 The promise of
this approach in the restorative stroke trial setting was
suggested by recent TMS8 and fMRI9 studies. Possibly, one
day, such imaging measures might be used to define treat-
ment dose and duration at the level of the individual patient.
Imaging measures might also serve as a marker of treat-
ment effect. Such data might provide insight into treatment
mechanism, which might secondarily guide features of restor-
ative trial design. For example, fMRI studies have described
changes in laterality10 or size of motor system activation11 in
relation to a motor-based therapy. Such results might guide
entry criteria (don’t enroll patients with massive motor
system injury), and might ultimately prove heuristic in the
refinement of many aspects of restorative stroke trial design.
Summary
A large number of restorative therapies are under study.
Measures of CNS injury and function can be used in many
different ways to assist clinical trials of these therapies.
Imaging measures hold promise to improve the ability of
restorative therapies to reduce disability after stroke.
Disclosures
None.
References
1. Kawamata T, Dietrich W, Schallert T, Gotts J, Cocke R, Benowitz L,
Finklestein S. Intracisternal basic fibroblast growth factor (bFGF)
enhances functional recovery and upregulates the expression of a
molecular marker of neuronal sprouting following focal cerebral
infarction. Proc Natl Acad Sci. 1997;94:8179–8184.
2. Kolb B, Morshead C, Gonzalez C, Kim M, Gregg C, Shingo T, Weiss S.
Growth factor-stimulated generation of new cortical tissue and functional
recovery after stroke damage to the motor cortex of rats. J Cereb Blood
Flow Metab. 2007;27:983–997.
3. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in
combination with physiotherapy on functional motor recovery after
stroke: A prospective, randomised, double-blind study. Lancet. 2001;358:
787–790.
4. Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D, Giuliani
C, Light KE, Nichols-Larsen D. Effect of constraint-induced movement
therapy on upper extremity function 3 to 9 months after stroke: The excite
randomized clinical trial. Jama. 2006;296:2095–2104.
5. Stinear CM, Barber PA, Smale PR, Coxon JP, Fleming MK, Byblow WD.
Functional potential in chronic stroke patients depends on corticospinal
tract integrity. Brain. 2007;130:170–180.
6. Cramer SC, Parrish TB, Levy RM, Stebbins GT, Ruland SD, Lowry DW,
Trouard TP, Squire SW, Weinand ME, Savage CR, Wilkinson SB,
Juranek J, Leu SY, Himes DM. Predicting functional gains in a stroke
trial. Stroke. 2007;38:2108–2114.
7. The IMS II Trial Investigators. The interventional management of stroke
(IMS) ii study. Stroke. 2007;38:2127–2135.
8. Koski L, Mernar T, Dobkin B. Immediate and long-term changes in
corticomotor output in response to rehabilitation: Correlation with func-
tional improvements in chronic stroke. Neurorehabil Neural Repair.
2004;18:230–249.
9. Dong Y, Dobkin BH, Cen SY, Wu AD, Winstein CJ. Motor cortex
activation during treatment may predict therapeutic gains in paretic hand
function after stroke. Stroke. 2006;37:1552–1555.
10. Carey J, Kimberley T, Lewis S, Auerbach E, Dorsey L, Rundquist P,
Ugurbil K. Analysis of fMRI and finger tracking training in subjects with
chronic stroke. Brain. 2002;125:773–788.
11. Takahashi CD, Der-Yeghiaian L, Le V, Motiwala RR, Cramer SC.
Robot-based hand motor therapy after stroke. Brain. 2008;131:425–437.
Figure. The time course of behavioral recovery is displayed for
three idealized patients. Stroke can be considered as having
three main phases. The acute phase is measured in hours, with
treatment approaches focused on salvaging threatened tissue. A
subacute phase measured in weeks follows, during which spon-
taneous growth-related changes might define restorative ther-
apy targets. These changes subsequently decline in the chronic
phase, which lasts an average of 8 years, as behavioral recov-
ery is on a plateau. The success of chronic phase restorative
interventions, ranging from activity-based to pharmacological,
suggests some restorative targets remain for years poststroke.
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